ClinicalTrials.gg
CompletedNCT00094328BATTUpdated Jun 26, 2018Results posted

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

A Phase 2 interventional study of Bicalutamide and Anastrozole in Puberty, Precocious, sponsored by AstraZeneca. Completed at 15 sites in 6 countries. Open to male participants aged 2 Years to 13 Years. Per ClinicalTrials.gov, last updated 2018-06-26.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
2 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Puberty, Precocious with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Puberty, Precocious · United States.

Enrollment
13th of 15
14 · median 55
Started
2004
the only one that year
Phase 2
5 of 21
1 open now
Registered
5th of 21
by date
Lead sponsor
2 of 21
AstraZeneca

Among the 21 studies in Puberty, Precocious with a site in United States, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 5 in phase 2, and was the 5th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

4 of the 21 studies in Puberty, Precocious with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Puberty, Precocious with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .

03

Conditions studied

  • Puberty, Precocious

Browse trials for

Keywords

  • Testotoxicosis
  • Familial Male-limited Precocious Puberty (FMPP)
04

Who can participate

Ages eligible
2 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written of parent/legal guardian and subject assent (as needed by local requirements)
  • Male aged 2 years and over
  • Diagnosis of testotoxicosis based on the following:
  • Clinical features of Progressive sexual precocity documented by Tanner staging and evidence of symmetrical testicular enlargement
  • Clinical features of significantly advanced bone age (defined as bone age of at least 12 months beyond chronological age)
  • Pubertal levels of serum testosterone
  • Prepubertal levels of serum gonadotropins
  • Lack of an increase in serum gonadotropin levels following GnRH stimulation
  • Other pathology excluded by:
  • Undetectable plasma b human chorionic gonadotropin (bHCG). Samples with values below the LOQ will be reported as "\<10 IU/L" which in the clinical setting equate to 'undetectable'.
  • Normal levels of 17-hydroxyprogesterone (17-OHP)
  • Normal levels of dehydroepiandrosterone sulphate (DHEAS)
  • Naive to anti androgen receptor therapy:

(Note: Ketoconazole and Spironolactone are considered acceptable as is prior use of anastrozole or other aromatase inhibitors)

  • A documented reliable height measurement taken > 6 months prior to study enrollment. Additionally for subjects who have previously received ketoconazole or spironolactone treatment, a documented reliable height measurement taken immediately prior to beginning this treatment.

(Note: for subjects who received such previous treatment only a single assessment is needed if it was taken immediately prior to beginning treatment and > 6 months prior to study entry)

  • Subjects should be free of endocrine or other effects of previous treatment for testotoxicosis prior to study entry: to ensure this there should be 15 days or 4 drug half lives (whichever is the longer) from prior medication for testotoxicosis.

Exclusion criteria

Exclusion Criteria:

  • Evidence of central precocious puberty as demonstrated by GnRH stimulation test
  • Serum concentration of total or direct , GGT, or ALT greater than 1.5 times the for age
  • Serum concentration of creatinine greater than 1.5 times the upper limit of normal for age
  • Any concomitant medical condition that, in the opinion of the investigator, may expose a subject to an unacceptable level of safety risk or that affects subject compliance
  • Known to any of the study medications
  • Participation in a clinical study at the time of enrollment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Other
    Bicalutamide with Anastrozole

    Bicalutamide in combination with Anastrozole

    Drug: Bicalutamide · Drug: Anastrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Growth Rate (cm/Year)

    Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, based on raw height data (cm/year).

    Time frame: Assessed after 12 months treatment

  2. Change in Growth Rate (SD Units)

    Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, calculated after adjustment for the chronological age of the patient (expressed as a standard deviation \[SD\] score).

    Time frame: Assessed after 12 months treatment

Secondary outcomes

  1. Change in Growth Rate (cm/Year)

    Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.

    Time frame: Assessed after 6 months treatment

  2. Change in Growth Rate (SD Units)

    Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.

    Time frame: Assessed after 6 months treatment

  3. Change in Bone Age Maturation Rate (cm/Year)

    Radiographs were used to assess the bone age at ≥6 months pre-study, baseline, 6 and 12 months. The rate of change in bone age at baseline was calculated from a radiograph taken at least 6 months prior to study enrolment. The change in bone maturation after 6 months of treatment was calculated relative to the rate of change in bone age during the ≥ 6 months pre-study period.

    Time frame: Assessed after 6 and 12 months treatment

  4. Change in Bone Age to Chronological Age Ratio

    Change in bone age to chronological age ratio after 6 and 12 months treatment relative to the baseline ratio for all patients.

    Time frame: Assessed after 6 and 12 months of treatment

  5. Number of Patients With Height Between 5th and 95th Percentile

    The number of patients whose height lies between the 5th and 95th percentiles (using the percentile tables on the WHO database) for chronological age at the 12 month assessment.

    Time frame: Assessed after 3, 6, 9 and 12 months of treatment

  6. Change in Predicted Adult Height (PAH)

    Radiographs are used to assess the bone age, the change in predicted adult height (PAH) is calculated from the bone age using the Bayley and Pinneau Method. The change in PAH is be calculated by subtracting the PAH at baseline from the PAH at 12 months.

    Time frame: Assessed after 12 months treatment

  7. Change in Average Testicular Volume

    Testicular volume of both testes was measured using either ultrasound or an orchidometer. Testicular volume was measured at baseline and at 6 and 12 months. The change in testicular volume from baseline was calculated for the left and right testicle as well as the average across both testes by subtracting the baseline volume from the volumes at 6 and 12 months within each patient.

    Time frame: Assessed after 6 and 12 months of treatment

07

Results

Posted Jul 9, 2009

Participant flow

The first patient was enrolled on 22 November 2004 and the last patient completed the 12 months visit on 7 May 2008. Patients were allocated treatment at 9 centres in 3 countries: India, the UK and the USA. Care for two patients, transferred from one US to a new approved US centre, therefore, patients were treated at 10 centres in total

Participant flow — Overall Study
MilestoneOpen Label Bicalutamide With Anastrozole
Started14
Completed13
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange in Growth Rate (cm/Year)

Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, based on raw height data (cm/year).

Time frame:
Assessed after 12 months treatment
Reported as:
Mean · cm/year
Change in Growth Rate (cm/Year)
cm/yearOpen Label Bicalutamide With Anastrozole
Change in Growth Rate (cm/Year)-1.62 ± 5.13
Statistical analysis
  • Open Label Bicalutamide With Anastrozole · t-test, 2 sided · p = 0.278 · Mean difference (final values): -1.62 · 95% CI -4.72 to 1.48
PrimaryChange in Growth Rate (SD Units)

Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, calculated after adjustment for the chronological age of the patient (expressed as a standard deviation \[SD\] score).

Time frame:
Assessed after 12 months treatment
Reported as:
Mean · SD units
Change in Growth Rate (SD Units)
SD unitsOpen Label Bicalutamide With Anastrozole
Change in Growth Rate (SD Units)-0.07 ± 1.78
Statistical analysis
  • Open Label Bicalutamide With Anastrozole · t-test, 2 sided · p = 0.882 · Median difference (final values): -0.07 · 95% CI -1.15 to 1.00
SecondaryChange in Growth Rate (cm/Year)

Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.

Time frame:
Assessed after 6 months treatment
Reported as:
Mean · cm/year
Change in Growth Rate (cm/Year)
cm/yearOpen Label Bicalutamide With Anastrozole
Change in Growth Rate (cm/Year)-0.70 ± 5.77
SecondaryChange in Growth Rate (SD Units)

Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.

Time frame:
Assessed after 6 months treatment
Reported as:
Mean · SD units
Change in Growth Rate (SD Units)
SD unitsOpen Label Bicalutamide With Anastrozole
Change in Growth Rate (SD Units)-0.14 ± 1.67
SecondaryChange in Bone Age Maturation Rate (cm/Year)

Radiographs were used to assess the bone age at ≥6 months pre-study, baseline, 6 and 12 months. The rate of change in bone age at baseline was calculated from a radiograph taken at least 6 months prior to study enrolment. The change in bone maturation after 6 months of treatment was calculated relative to the rate of change in bone age during the ≥ 6 months pre-study period.

Time frame:
Assessed after 6 and 12 months treatment
Reported as:
Mean · cm/year
Change in Bone Age Maturation Rate (cm/Year)
cm/yearOpen Label Bicalutamide With Anastrozole
After 6 months treatment-2.03 ± 0.38
After 12 months treatment-2.29 ± 0.51
SecondaryChange in Bone Age to Chronological Age Ratio

Change in bone age to chronological age ratio after 6 and 12 months treatment relative to the baseline ratio for all patients.

Time frame:
Assessed after 6 and 12 months of treatment
Reported as:
Mean · Ratio
Change in Bone Age to Chronological Age Ratio
RatioOpen Label Bicalutamide With Anastrozole
After 6 months treatment-0.09 ± 0.14
After 12 months treatment-0.24 ± 0.18
SecondaryNumber of Patients With Height Between 5th and 95th Percentile

The number of patients whose height lies between the 5th and 95th percentiles (using the percentile tables on the WHO database) for chronological age at the 12 month assessment.

Time frame:
Assessed after 3, 6, 9 and 12 months of treatment
Reported as:
Number · Participants
Number of Patients With Height Between 5th and 95th Percentile
ParticipantsOpen Label Bicalutamide With Anastrozole
After 3 months treatment3
After 6 months treatment3
After 9 months treatment3
After 12 months treatment3
SecondaryChange in Predicted Adult Height (PAH)

Radiographs are used to assess the bone age, the change in predicted adult height (PAH) is calculated from the bone age using the Bayley and Pinneau Method. The change in PAH is be calculated by subtracting the PAH at baseline from the PAH at 12 months.

Time frame:
Assessed after 12 months treatment
Reported as:
Mean · cm
Change in Predicted Adult Height (PAH)
cmOpen Label Bicalutamide With Anastrozole
Change in Predicted Adult Height (PAH)6.21 ± 3.93
SecondaryChange in Average Testicular Volume

Testicular volume of both testes was measured using either ultrasound or an orchidometer. Testicular volume was measured at baseline and at 6 and 12 months. The change in testicular volume from baseline was calculated for the left and right testicle as well as the average across both testes by subtracting the baseline volume from the volumes at 6 and 12 months within each patient.

Time frame:
Assessed after 6 and 12 months of treatment
Reported as:
Mean · mL
Change in Average Testicular Volume
mLOpen Label Bicalutamide With Anastrozole
After 6 months treatment1.46 ± 2.29
After 12 months treatment2.69 ± 2.51

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Bicalutamide With Anastrozole0/14 (0%)0/14 (0%)13/14 (92.9%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventOpen Label Bicalutamide With Anastrozole
GynaecomastiaReproductive system and breast disorders7/14
Precocious PubertyEndocrine disorders6/14
VomitingGastrointestinal disorders5/14
HeadacheNervous system disorders3/14
PyrexiaGeneral disorders3/14
Abdominal PainGastrointestinal disorders2/14
AcneSkin and subcutaneous tissue disorders2/14
Breast TendernessReproductive system and breast disorders2/14
ConjunctivitisEye disorders2/14
Croup InfectiousInfections and infestations2/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Open Label Bicalutamide With Anastrozole
Median3.5 (2 to 9)
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Bicalutamide With Anastrozole
Female0
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open Label Bicalutamide With Anastrozole
Race — Caucasian12
Race — Black1
Race — Other1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open Label Bicalutamide With Anastrozole
Ethnic group — Hispanic/Latino1
Ethnic group — African/American1
Ethnic group — Asian3
Ethnic group — Not Applicable9
08

Study locations

15 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Jacksonville, Florida 32207, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Minneapolis, Minnesota 55416, United States
  • Research Site
    Tulsa, Oklahoma 74136, United States
  • Research Site
    Philadelphia, Pennsylvania 19134, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Temple, Texas 76508, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    London, Ontario N6A 4G5, Canada
  • Research Site
    Montpellier Cedex, 34295, France
  • Research Site
    Chennai, 600020, India
  • Research Site
    New Dehli, 110029, India
  • Research Site
    Moscow, 117036, Russian Federation
  • Research Site
    London, WC1N 3JH, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2004 to primary completion in May 2008, 42 months.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2004
First posted
Oct 18, 2004
StartActual
Nov 22, 2004
Primary completionActual
May 22, 2008
CompletionActual
Dec 6, 2017
Results first posted
Jul 9, 2009
Last update
Jun 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00094328
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 18, 2004
Start date
Nov 22, 2004
Primary completion
May 22, 2008
Completion
Dec 6, 2017
Results posted
Jul 9, 2009
Last update
Jun 26, 2018

Study contacts

Yuri E Rukazenkov, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bicalutamide · Anastrozole

Start the discussion